- Home
- SCHW vs NVS Comparison
SCHW vs NVS Comparison
Compare SCHW & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCHW | NVS |
|---|---|---|
| Founded | 1971 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.3B | 266.5B |
| IPO Year | 1987 | 1991 |
Fundamental Metrics
Financial Performance| Metric | SCHW | NVS |
|---|---|---|
| Price | $103.97 | $145.04 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 5 |
| Target Price | $113.44 | ★ $118.00 |
| AVG Volume (30 Days) | ★ 7.6M | 1.4M |
| Earning Date | 01-21-2026 | 02-04-2026 |
| Dividend Yield | 1.06% | ★ 1.79% |
| EPS Growth | ★ 66.73 | N/A |
| EPS | 4.27 | ★ 7.30 |
| Revenue | $22,914,000,000.00 | ★ $56,372,000,000.00 |
| Revenue This Year | $24.59 | $9.38 |
| Revenue Next Year | $10.86 | $2.69 |
| P/E Ratio | $23.85 | ★ $19.88 |
| Revenue Growth | ★ 21.67 | 12.88 |
| 52 Week Low | $65.88 | $97.72 |
| 52 Week High | $104.98 | $146.35 |
Technical Indicators
Market Signals| Indicator | SCHW | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 59.35 | 66.64 |
| Support Level | $99.69 | $142.82 |
| Resistance Level | $104.98 | $146.35 |
| Average True Range (ATR) | 2.38 | 2.16 |
| MACD | -0.18 | 0.08 |
| Stochastic Oscillator | 64.84 | 87.87 |
Price Performance
Historical ComparisonAbout SCHW Charles Schwab Corporation (The)
Charles Schwab is one of the largest retail-oriented financial-services companies in the US, with $11.6 trillion in client assets across its brokerage, banking, asset management, custody, financial advisory, and wealth-management businesses at the end of the third quarter. While best known for its retail brokerage offering, Schwab generates the lion's share of its revenue and profits through its Charles Schwab Bank and asset management segments. The firm is a dominant player in registered investment advisor custody, with over 40% market share, and has recently pushed into wealth management with robo-advisory, direct indexing, and other managed-investment solutions.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.